Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
7 evidence topics · 7 sources
Nursing considerations before and during instillation
Patient education and follow-up after instillation
Response surveillance schedule in BOND-003
Re-induction for persistent disease at 3 months
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote